Table 3.

Risk of adverse pregnancy outcomes in each midterm eGFR subgroup

Adverse pregnancy outcomesOR95% CIP ValueAdjusted ORa95% CIP Value
Composite outcome
 eGFR≥1501.921.36 to 2.77<0.0011.971.34 to 2.89<0.001
 90≤eGFR<1201.651.32 to 2.06<0.0011.571.23 to 2.00<0.001
 60≤eGFR<907.343.16 to 17.07<0.0014.931.97 to 12.31<0.001
Preterm birth
 eGFR≥1502.361.63 to 3.42<0.0012.451.65 to 3.64<0.001
 90≤eGFR<1201.711.35 to 2.17<0.0011.631.26 to 2.11<0.001
 60≤eGFR<907.023.14 to 15.67<0.0014.842.00 to 11.74<0.001
Low birth weight
 eGFR≥1501.991.33 to 2.960.0011.981.29 to 3.020.002
 90≤eGFR<1201.321.02 to 1.720.041.270.96 to 1.680.09
 60≤eGFR<903.881.76 to 8.580.0012.491.03 to 5.990.04
 eGFR≥1501.310.61 to 2.820.481.350.62 to 2.940.46
 90≤eGFR<1201.841.21 to 2.810.0041.771.14 to 2.760.01
 60≤eGFR<909.854.10 to 23.69<0.00110.994.45 to 27.15<0.001
  • eGFR measured in ml/min per 1.73 m2. OR, odds ratio, 95% CI, 95% confidence interval.

  • a Adjusted for age, pregestational body mass index, weight gain until delivery, baseline hypertension, diabetes mellitus and hypertension during pregnancy, previous history of stillbirth/miscarriage, multiparity, and hospitalization status at the time of eGFR measurement. For analysis of preeclampsia risk, hypertension during pregnancy was not adjusted. As a substantial number of women had missing information for baseline body mass index (n=573) and weight gain (n=446), missing value imputation by the classification and regression trees method was performed in multivariable analyses.